Objectives. The overall non-response rate to biologics remains 30–40% for patients with RA
resistant to MTX. The objective of this study was to predict responsiveness to the anakinra …

Our aim was to identify differentially expressed (DE) genes and biological processes that
may help predict patient response to biologic agents for rheumatoid arthritis (RA). Using the …

Introduction About 30% of rheumatoid arthritis patients fail to respond adequately to TNFα-
blocking therapy. There is a medical and socioeconomic need to identify molecular markers …

The prediction of response (or non-response) to anti-TNF treatment for rheumatoid arthritis
(RA) is a pressing clinical problem. We conducted a genome-wide association study using …

Background According to EULAR recommendations, biologic DMARDs (bDMARDs) such as
tumor necrosis factor inhibitor, tocilizumab (TCZ), and abatacept (ABT) are in parallel when …

Background: Several studies have employed microarray-based profiling to predict response
to tumor necrosis factor-alpha inhibitors (TNFi) in rheumatoid arthritis (RA); yet efforts to …

ABSTRACT Interleukin-1 receptor antagonist (IL-1Ra) is a member of the IL-1 gene family,
which blocks IL-1-mediated signal t ransduction. In rheumatoid art h ri tis (RA), recombinant …

Introduction To identify markers and mechanisms of resistance to adalimumab therapy, we
studied global gene expression profiles in synovial tissue specimens obtained from severe …

Although many drugs and therapeutic strategies have been developed for rheumatoid
arthritis (RA) treatment, numerous patients with RA fail to respond to currently available …

Background TNF alpha blockade agents like infliximab are actually the treatment of choice
for those rheumatoid arthritis (RA) patients who fail standard therapy. However, a …